GHK-Cu and Collagen: What the Skin Studies Actually Measured

Copper peptide serums sell on three words: collagen, firmness, repair. Behind those words sits a research record that is older and more specific than the marketing suggests. It runs from fibroblast dishes in Reims in 1988, through a randomised trial in diabetic foot ulcers in 1994, to a handful of 12-week cosmetic studies in women around 50. This post sets out what each of those studies measured, and where the claims on a serum box stop being supported by them.

The fibroblast experiments that started it

The first hard number came from François-Xavier Maquart's laboratory in Reims. His team added GHK-Cu to cultured fibroblasts and measured collagen synthesis. Stimulation began between 10 to the minus 12 and 10 to the minus 11 molar, peaked at 10 to the minus 9 molar, and did not depend on the cells dividing faster (Maquart et al., FEBS Letters, 1988).

One nanomolar is a very small amount. It is about a hundred times lower than the 10 to the minus 7 molar plasma level that later reviews give for a 20-year-old, which is part of why the finding was taken seriously.

The same paper proposed a mechanism. The GHK sequence sits within the alpha 2(I) chain of type I collagen, so when proteases break down damaged collagen at a wound they may release GHK locally. That made ghk-cu a candidate for an early repair signal rather than just a nutrient.

Breakdown as well as build-up

What the serum adverts leave out is that GHK-Cu stimulated breakdown too. Pickart's 2015 review summarises work by Borel and Maquart's group showing the peptide, at 1 to 10 nanomolar, increased both synthesis and breakdown of collagen and glycosaminoglycans, and modulated matrix metalloproteinases and their inhibitors TIMP-1 and TIMP-2 (Pickart, Vasquez-Soltero and Margolina, BioMed Research International, 2015).

Siméon and colleagues reported in Life Sciences in 2000 that GHK-Cu raised matrix metalloproteinase-2 expression in fibroblast cultures. Wegrowski, Maquart and Borel had earlier shown it stimulated sulfated glycosaminoglycan synthesis.

The honest summary is remodelling, not simple collagen boosting. A dish of fibroblasts given copper peptide ghk-cu makes more collagen, more decorin, more dermatan and chondroitin sulfate, and also more of the enzymes that take old matrix apart.

Animal wound models: what was measured

The animal record is broader than the human one. The 2015 review lists accelerated wound healing with more blood vessel formation and higher antioxidant enzyme levels in rabbits, systemic wound healing effects in rats, mice and pigs, and healing of foot pad wounds in dogs.

A 2001 paper by McCormack and colleagues, also summarised in the review, found GHK-Cu restored replicative capacity to fibroblasts taken from patients after radiation therapy. These were cells in culture, not irradiated skin in a living patient.

Each of these models measured something concrete: wound area over time, vessel counts on histology, enzyme activity. None of them measured wrinkles, and none of them used a cream. Researchers who buy ghk-cu for wound-model work are repeating this tier of the record.

The one randomised wound trial in people

There is exactly one multicentre randomised trial. Mulder and colleagues tested a GHK-Cu gel, trade name Iamin Gel, against vehicle in diabetic neuropathic plantar ulcers. The design was evaluator-blinded and placebo-controlled (Mulder et al., Wound Repair and Regeneration, 1994).

The gel arm reached a median 98.5% closure of ulcer area against 60.8% for vehicle, and the authors reported closure three times faster than standard care. In ulcers larger than 100 square millimetres the gap was wider: 89.2% median closure against minus 10.3% for vehicle.

The authors stressed that treatment had to begin immediately after debridement to get the effect. The trial is now 32 years old and remains the only human wound trial cited in the 2015 and 2018 reviews.

The cosmetic trials: 71, 41 and 67 women

The facial studies are the ones the skincare industry leans on. Pickart's 2015 review describes three, all 12 weeks long, all in women with mild to advanced photodamage.

• A facial cream tested on 71 women, which improved laxity, clarity, fine lines, wrinkle depth, skin density and thickness
• An eye cream on 41 women, compared with placebo and a vitamin K cream, which did better than both on lines, wrinkles and density
• A cream applied twice daily by 67 women aged 50 to 59, where biopsies showed increased keratinocyte proliferation

An earlier study by Abdulghani and colleagues, published in 1998 in Disease Management and Clinical Outcomes, applied creams to the thigh for a month and examined biopsies. Collagen production increased in 70% of the women on the GHK-Cu cream, against 50% on vitamin C and 40% on retinoic acid, according to the review.

These are real measurements, including histology. They are also small, short, and reported by the peptide's discoverer, whose paper lists an address at Skin Biology in Bellevue, Washington. NPR, reporting in September 2026, described the human studies as generally small trials funded by the cosmetic industry (NPR, 2026). For context on how this research fits the wider record, see the companion post on the history of GHK-Cu research since 1973.

How much is in a serum, and does it get through?

Here the gap between study and shelf opens up. The Cosmetic Ingredient Review Expert Panel assessed copper tripeptide-1, the INCI name for GHK-Cu, and found typical use concentrations in cosmetics of under 10 parts per million. The Panel concluded the ingredient was safe in cosmetics at those concentrations (Johnson et al., International Journal of Toxicology, 2018).

Ten parts per million is 10 micrograms per gram of cream. That is a different proposition from a laboratory experiment where research-grade ghk-cu is weighed out to a known nanomolar concentration in culture medium.

Penetration is the other open question. David Goldberg, a clinical professor at the Icahn School of Medicine at Mount Sinai, told NPR that the molecule does not easily penetrate deeper into the skin when applied topically. Whether a 10 ppm cream delivers nanomolar GHK-Cu to dermal fibroblasts has not been measured in a published trial.

What the marketing claims that the studies do not

Reading product pages against the papers, four kinds of claim stand out as going further than the data.

1. "Clinically proven to rebuild collagen": the collagen data are from cultured fibroblasts and one 1998 thigh-biopsy study of a cream, not from facial trials measuring collagen directly.
2. "Repairs skin barrier": the wound data are from animals and one diabetic ulcer trial of a prescription-style gel, not from intact skin.
3. "Works at any concentration": the fibroblast effect peaked at 1 nanomolar and fell off above it, so more is not better even in a dish.
4. "Results in days": every human study ran 4 to 12 weeks.

None of this means the peptide does nothing on skin. It means the serum claims rest on three small 12-week studies and a 1998 biopsy paper, while the fibroblast and wound-model work is what a laboratory can actually reproduce.

LynxLab stocks GHK-Cu for research use in 50mg and 100mg vials from £23.99, tested to 99% purity with the lab report on the product page. At nanomolar working concentrations a ghk-cu 50mg vial covers a great many culture plates. Independent lab reports are what separate a research supplier from a serum brand.

Anyone reconstituting the powder for a culture assay should also read the practical notes on why GHK-Cu is blue, and how it is stored. Buyers comparing a ghk-cu uk supplier against an overseas one should ask for the same batch report either way.

Frequently asked questions

Does GHK-Cu increase collagen?

In cultured fibroblasts, yes: Maquart's 1988 FEBS Letters paper measured increased collagen synthesis from picomolar concentrations with a peak at 1 nanomolar. In people, one 1998 study found more collagen on thigh biopsies after a month of cream in 70% of participants. GHK-Cu also increased matrix-degrading enzymes, so the effect is remodelling rather than one-way build-up.

What did the GHK-Cu clinical trials show?

The only randomised multicentre trial was in diabetic foot ulcers in 1994, where a GHK-Cu gel reached 98.5% median closure against 60.8% for vehicle. Three 12-week cosmetic studies in 71, 41 and 67 women reported improved laxity, wrinkle depth and skin density. No randomised trial of systemic GHK-Cu in people has been published.

How much GHK-Cu is in skincare products?

The Cosmetic Ingredient Review found typical use concentrations of copper tripeptide-1 in cosmetics below 10 parts per million, and judged it safe at those levels in 2018. Laboratory experiments use defined nanomolar concentrations in culture medium instead, which is a different measurement from a percentage in a cream.

Does GHK-Cu penetrate skin when applied topically?

That has not been measured in a published trial. A dermatologist quoted by NPR in 2026 said the molecule does not easily penetrate deeper into the skin as a topical, and typical cosmetic concentrations are under 10 parts per million. The fibroblast effects were measured with the peptide added directly to culture medium.

Sources

• Stimulation of collagen synthesis in fibroblast cultures by GHK-Cu, FEBS Letters, 1988
• GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration, BioMed Research International, 2015
• Enhanced healing of ulcers in patients with diabetes by topical GHK-Cu, Wound Repair and Regeneration, 1994
• Safety Assessment of Tripeptide-1, Hexapeptide-12 and Their Metal Salts as Used in Cosmetics, International Journal of Toxicology, 2018
• People are injecting copper peptides ahead of the science, NPR, 2026